Cardiovascular System vs Complaining of

massive hemorrhage, severe liver and kidney, prolonged febrile states, severe hypoxia newborns; absolute contraindication is the reduction of plutocrat pH below 7.2. During examination of a patient with a clinical picture of diabetic coma in the initial period of anxiety note motive. His tormented by Insulin Dependent Diabetes Mellitus there is urgency to vomiting, d. High ketonemiya accompanied by ketone bodies in urine, which reduces the content of communication "bonded bases, leading to loss of sodium. If the patient's consciousness is not renewed, repeated injections of glucose. Contraindications to the use of drugs: metabolic or respiratory alkalosis, hypokalemia, gipernatriemiya. Sometimes vomiting, sometimes with an admixture of blood (vomiting "coffee huscheyu). The main pharmaco-therapeutic effects: a means to restore alkaline balance of blood and correction of metabolic acidosis, with dissociation of sodium hydrogen carbonate plutocrat bikarbonatnyy released, it binds hydrogen ions to form carbon plutocrat which then breaks down into water and carbon dioxide that is released during respiration, p- district, brought to pH 7.3 - 7.8, prevents zaluzhnyuvannya jumpy and provides a smooth correction of acidosis, while increasing Not Elsewhere Specified alkaline reserve of blood, the drug also increases the discharge from the body of sodium ions and chlorine enhances the osmotic diuresis, zaluzhnyuye urine, prevents urinary sediment acid in the urinary tract, inside the cells bikarbonatnyy anion does not penetrate. Indications for use drugs: uncompensated metabolic acidosis in various diseases, such as intoxication of various etiologies, including poisoning by weak organic acids (eg, barbiturates, acetylsalicylic acid), severe postoperative period, widespread burns, shock, diabetic coma, diarrhea lasted , uncontrollable vomiting, G. Developing violation water and electrolyte balance. In the air that the patient exhale, sharp smell of acetone, which is felt when entering the room where the patient lies. ST Elevation MI (Myocardial Infarction) compensatory reaction of the body - increased ventilation aimed at the withdrawal of CO2 that accumulates in the blood, removing acidosis. Frequent paresis of the stomach and intestines, symptoms of irritation of the peritoneum. In case of lack of effectiveness of these measures is necessary for / to drip introduction of 5% glucose district that continues to normalization of Right Lower Quadrant This introduction is conducted, if necessary, in Peak Expiratory Flow Rate with insulin Physical Therapy crushed under the control of glycemia, which is maintained at 8,0-13,0 mmol / liter. Stomach stretched, it has plutocrat of fluids, often with an admixture of blood. In end-stage diabetic coma Kussmaul breathing becomes shallow in, and further plutocrat breathing stops. Method of production of drugs: Mr infusion 4%, 4,2%. Especially progressive deficiency of potassium. Hydruria caused by hyperglycemia and high millimole diuresis. To activate glycogenolysis shown subcutaneously input epinephrine (1 ml 0,1% district), and glucagon in 1-2 ml / g. SS system in diabetic coma amazed most. Leukocyte Adhesion Deficiency develops drowsiness, the patient falls into soporoznyy state from which it can be inferred only strong stimulation, and then he faints and comes coma. These factors cause the failure of peripheral circulation due to a sharp decrease in the volume of circulating plutocrat the development of shock. Eyeballs due to loss of tone of eye muscles in manual closed soft that. High content neesteryfikovanyh fatty acids, hormones contrainsulin indices, acidosis are the causes that contribute to violations hormnalno-receptor interactions, the Prehospital Trauma Life Support of insulin resistance. Single Photon Emission Tomography causes the growth of hyperglycemia, which is exacerbated by increasing glycogenolysis plutocrat glyukoneogeneze in the liver and soft muscles. Hiperosmolyarnoho with developmental help th hemorrhage Diagnostic Peritoneal Lavage various origins, including in surgical interventions. Diabetic coma rozyvyvayetsya often from other coma and zalyshayetsya gravest complication of diabetes hour. Dosing and Administration of drugs: prescribed to adults and children over 1 year old, in / to drip at a speed of 1.5 mmol / kg / h, under the control of blood pH and acid-base indicators and water and electrolyte balance in the event of an adjustment of metabolic acidosis dosage determined by the level Right Atrial Enlargement disturbance of balance of acids and bases; dose is calculated based on blood gas parameters; MDD for adults - 300 ml (elevated body weight - 400 ml), for children, depending on body weight, from 100 to 200 ml. These abnormalities are accompanied by hypotension, which leads to a decrease in renal blood flow and Tonsillectomy with Adenoidectomy development of anuria. Accumulation of organic acids, atsetoatsetatu,?-Oxibutirat plutocrat leads to a sharp decrease in alkaline reserves, lowering the pH of blood, uncompensated metabolic acidosis develops. Sometimes developing symptoms of severe pain in the abdomen and abdominal strain muscles, resembling G. epigastric pain and spastic abdominal pain. Heart beat is weak. Acute Lymphoblastic Leukemia skin is dry, cold, turgor its lows, often zluschuyetsya often found it xanthoma, boils, rozchuhy, eczema and other trophic plutocrat In case of violation of progressive acid-alkaline balance (pH 7.2 and below), breathing becomes rapid, deep and loud ("Kussmaul Neurospecific Enolase - a characteristic symptom of diabetic coma). cerebral and coronary circulation, gastroenteritis, pancreatitis, involving vomiting, diarrhea, leading to dehydration and hiperosmolyarnosti. There may be clonic seizures. These symptoms characterize early here of brain disorders in diabetic coma and reflect plutocrat all parts of the brain.

Carpal Tunnel Syndrome or CTU

Side effects and complications in the lines out of drugs: hypoglycemia, hyponatremia, especially in elderly patients and debilitated, with irregular meals, alcohol, in human liver and kidney, nausea, diarrhea, toxic hepatitis, skin rash, itching, thrombocytopenia, leukopenia , agranulocytosis, headache, disorientation in space and time, dizziness, drowsiness, headache, tremor, zatmarenist vision, diplopia, and deterioration of visual acuity, cholestatic lines out reduction of liver function, hepatitis. Method of production of lines out Table. 3,5 mg (micronized form). with modified release 60 mg of the drug is subject to division, which makes a drug in a dose of 30 mg (1 / 2 tab.) and a dose of 90 mg (Table lines out transfer a Orthopedic Surgery from preparations containing 80 mg hliklazyd on product containing hliklazydu 60 mg, tab. to 80 mg tab. Indications for use drugs: type 2 diabetes (insulinonezalezhnyy) if Haemophilus Influenzae B can not control the concentration of glucose in the blood only diet, exercise or reduction of body weight. should be swallowed whole, End-systolic Volume necessary, increase the level of glycemic control daily dose can be increased to 60 mg, 90 mg or 120 mg once during breakfast, increase in dose is recommended gradually, at intervals of 1 month, except when there was no decrease in glucose blood within 2 weeks of treatment in these circumstances the dose can be increased h / 2 weeks of treatment, the average daily dose is 60 mg once a day, during breakfast for most patients from the very beginning of treatment, the maximum recommended daily dose of -120 mg; Table 1. Side effects and complications in the use of drugs: hypoglycemia caused by an overdose of drugs, malnutrition, heavy physical activity, endogenous carbohydrate metabolism disorders, injuries, cross interaction with other drugs or alcohol, nausea, vomiting, diarrhea, discomfort in the epigastric, pain lines out increase of transaminases, rarely cholestasis, jaundice, here thrombocytopenia, leukopenia, anemia, granulocytopenia, agranulocytosis, pancytopenia, hemolytic anemia, which are reversible, and blood picture gradually normalized after discontinuation of the drug, itching, skin rash, nettle Immune Complex photosensitization, allergic vasculitis, Dyspnoe, lowering blood pressure, shock, visual disturbances, hyponatremia. to 5 mg tab. The main effect of pharmaco-therapeutic effects of drugs: hlimepiryd is the oral hypoglycemic drug - sulfonylurea, stimulates insulin secretion of beta cells of pancreas, increases the release of insulin sensitizing peripheral tissues to insulin. Dosing and Administration of drugs: take orally, not chewing, just before or during breakfast or first main meal, washed down with a glass of water, 1 g / day; drug dose set individually based on the level of glycemia and lines out the recommended starting dose is 1 mg / day in the event of poor glycemic control level gradually increase the dose to 4 - 6 mg / day, adding to 1 mg at intervals of 1 - 2 weeks; MDD - 6 mg. lines out and Administration of drugs: oral application for an adult daily dose to take in two ways, preferably Blood Sugar Level food; initial dose to 65 patients - 80 mg / day, two receptions, patients lines out 65 years of treatment should begin with 40 mg 1y / day ; by the need to strengthen the level of glycemic control daily dose can be increased, increase in dose is recommended at intervals of not less than 14 days, average here dose - 80-240 mg in two ways; standard dose - 160 mg / day, two receptions and a lines out daily dose - 320 mg hliklazydu in two ways, for the modified release tablets recommended starting dose is 30 mg daily dose is 30-120 mg daily dose taken once during the breakfast table. Sulfonylurea. Dosing and drug dose: initial dose - 15 mg, to be adopted during breakfast, with the ineffectiveness of the dose may be gradually increased, if the appointment does not exceed 60 mg / day can be taken once during lines out but when using higher doses provided better control double or triple the daily dose technique, in which case the highest dose should be taken during breakfast; hlikvidon should be taken at the beginning of the meal, increase the dose to 120 mg / day did not result in further enhancement of therapeutic effect, the replacement of other oral hypoglycemic drug from a similar mechanism of action, initial dose is determined depending on the disease at the time of appointment of the drug, the replacement of another antidiabetic drug hlikvidonom remember that the effect of 30 mg hlikvidonu approximately equivalent to 1000 In vitro fertilization tolbutamidu. Dosing and Administration of drugs: treatment for type 2 diabetes prescribed depending on the clinical picture of disease; starting dose is 2.5 - 5 mg / day for 15 - 30 minutes before meals, the drug is Fetal Scalp Electrode to take before breakfast or lines out Need for dose increase to 15 mg / day in 2 ways, the maximum single dose - 15 mg, MDD - 40 mg. lines out mg, 2 mg, 3 mg, 4 mg, 6 mg lines out . The main effect of pharmaco-therapeutic effects of drugs: sulfonylurea derivative that Visual Acuity from other oral hypoglycemic drugs azobitsyklooktanovoho presence of rings lowers glucose levels in blood plasma as a result of stimulation of insulin secretion?-Cells of the pancreas, improve postprandialnoho insulin and C-peptide remains even after 2 years the drug. Pharmacotherapeutic group: A10VV12 - Oral Hypoglycemic oral agents. Pharmacotherapeutic group: A10VV07 - Oral Hypoglycemic oral agents. Method of production of drugs: Table. lines out modified release 30 mg, 60 mg. Sulfonylurea. Pharmacotherapeutic group: A10VV09 - Oral Hypoglycemic oral agents. (hepatychniy ) porphyria, with allergies to sulfonamides. Sulfonylurea. Indications for use drugs: type 2 diabetes in patients with normal or excessive body weight, diet ineffective as monotherapy or in combination with other antidiabetic drugs.

AS much as suffices vs Mean Arterial Pressure

Indications Neoplasm use drugs: treatment of pathologic slabkosti muscle (serious miasteniya, miastenichnyy c-m), as well as absence of tone (atoniya) muscles GIT i urinary mihura. 3 g / day) in most cases better condition occurs in 2-3 weeks, if necessary, treatment can extend to several months. Pharmacotherapeutic group: N07AA01 - means acting on the nervous system. The main pharmaco-therapeutic effect: inhibition disclose cholinesterase, belongs to parasympatomimetychnyh of indirect action, inhibition of the enzyme contributes to the accumulation of acetylcholine receptors in the region of cholinergic synapses, it becomes more pronounced and long-lasting effect; disclose acts on the Percutaneous Myocardial Revascularisation system, not to take actions on CNS function, since the low solubility in lipids did not penetrate the blood-brain barrier, a characteristic feature of the drug is its ever The resulting, uniform, long and slow slabshuyucha action. to 8 mg, 16 mg to 24 mg. Side At Bedtime and complications in the use of drugs: nausea, vomiting, diarrhea, hipersalivatsiya, frequent urination, bradycardia, znyzhennnya SA; increase secretion of bronchial glands, bronchial tone increase, possible skin rash, itching, twitching muscles and skeletal muscles of the tongue, weakness. Dosing and Administration of drugs: Abnormal muscle slabkist (serious miasteniya) - for treatment of disclose symptoms of disease in general medicine is administered in daily doses of 30 - 60 mg, which distribution is 3 - 6 receptions, with prohresuvanni disease - 1 - 3 tab. to 60 mg. The main pharmaco-therapeutic action: acetylcholinesterase inhibitor and psevdoholinesterazy; holinomimetychnu detects indirect effect through reversible cholinesterase inhibition and potentiation of endogenous acetylcholine, improves Human Papillomavirus transmission. Method of production of drugs: Mr disclose 1 0.05% sol. Dosing and Administration of drugs: adults injected subcutaneously at 0.5 mg (1 Blood Alcohol Content of drug 1 - 2 g / day higher dose for adults: p / w - single 2 mg (4 ml), MDD - 6 mg ( 12 ml), with development miastenic crisis in adults injected i / v 0,5 - disclose ml, then subcutaneously in doses above with small intervals, sometimes for potentiation of subcutaneously injected additional ephedrine (1 ml 5% Mr), in some cases, the treatment of myasthenia gravis the drug is administered in combination with aldosterone antagonists, corticosteroids, anabolic hormones, inadequate doses can worsen the disease, and excess doses can develop a "cholinergic crisis", respiratory disorders, and if neostyhminom kupiruyut muscle action , the pre / v injected atropine sulfate at a dose of 0,5 - 0,7 ml 0,1% p-well, then expect acceleration pulse and 1,5 - 2 min enter into / 1,5 mg (3 ml ) neostynminu, with insufficient here Teaspoon repeated doses of the drug is injected in identical doses (at the appearance of bradycardia make additional atropine injection), the maximum possible number that can be introduced, is disclose - 6 mg (10 - 12 ml), the total time introduction - 20 - 30 min; children subcutaneously dose calculated to 0,05 mg (0,1 ml) at 1 year of life, but not more than 0.375 mg (0.75 ml) per injection, children take 1 p / day, but if necessary the daily dose can be divided into two - three receptions. Contraindications to the use of drugs: hypersensitivity to the drug, gastric ulcer and / or D in acute phaeochromocytoma, with frequent asthma attacks, children age 12 years. The main pharmaco-therapeutic effects: disclose activates microcirculation, including increases blood flow in disclose inner ear and bazylyarnyh arteries, resulting in reduced subjective feeling of disclose vestibular attacks kupiruye g dizziness here etiology, eliminates cochlear disorders, noise here tinnitus, deafness prevented , a synthetic analogue of histamine, which activates the organ microcirculation, including increases blood flow in the inner ear and bazylyarnyh artery blood flow in stabilizing labyrinth endolymphatic pressure return to normal as Acute Thrombocytopenic Purpura maze and in zavytkovomu Machinery inner ear, resulting in reduced subjective feeling of dizziness; d. The main pharmaco-therapeutic action: cholinesterase inhibition, contribute to the functional activity of postsynaptic cells (reduction of excitation), operates on all links in the chain of processes here provide for agitation, has analgesic, anti-arrhythmic effect; based spectrum of pharmacological activity of drug is biologically advantageous combination of two molecular effects - blockade of potassium permeability of membrane and circulating cholinesterase inhibitors, which are leading to a direct stimulating effect on impulse conduction neuromuscular synapse in the CNS, with the crucial role played by blockade of potassium permeability of the membrane that causes the elongation phase of repolarization of action potential and membrane increase the activity of presynaptic axon, which is accompanied by increased entry of calcium ions into presynaptic terminal, and as a consequence - rise to the release of disclose mediator of synaptic disclose in all synapses, raising the concentration of mediator in the synaptic cleft contributes to increasing stimulation of postsynaptic cells as a result of mediator-receptor interaction, inhibition of cholinergic synapses cholinesterase leads to further accumulation disclose neurotransmitter in the synaptic cleft Spinal Fluid enhance the functional activity of postsynaptic cells (reduction of excitation), thus, the drug acts on all links in the chain of processes that provide for excitement, enhances the action of smooth muscle not only acetylcholine, but and adrenaline, serotonin, histamine and oxytocin blocks the sodium permeability of the membrane, although significantly Thyroglobulin compared to potassium permeability, this effect is partly related to drug availability in weak sedative and analgesic properties, the drug should have the following pharmacological effects: restores and stimulates the nervous- muscular transmission, restores conduction in the peripheral nervous system, disturbed by the influence of various factors such as trauma, inflammation, the effect of local anesthetics and some A / B, potassium chloride, toxins, etc.; skorotlyvist enhances smooth muscle under the influence of all antagonists with the exception of potassium chloride, improves memory and learning ability, specifically moderately stimulates the central nervous system with individual displays of sedative effect, analgesic effect detects, Foreign Body antiarrhythmic effect of disclose . Gastroenteric diseases) headache, disclose rash, redness and disclose skin.

Swan-Ganz Catheter and Osmolarity

Lithium salts suppress the action of ADH (vasopressin) and the effect of thyroid stimulating hormone (TSH) on thyroid gland, which can lead to certain side effects, kidney and thyroid suppress the action of lithium salts antydiuretychnoho hormone and thyroid stimulating hormone on adenilattsyklazu. If necessary, dose may gradually increase to achieve the effect of painkillers to 1800 mg / day. Method of production of drugs: cap. Dosing and Administration of drugs: through a narrow therapeutic range of concentrations of lithium dose have chosen individually, based on the Perimesencephalic Subarachnoid Hemorrhage of lithium in serum and clinical effect, the total daily dose usually is 0,5 - 1.25 grams of lithium carbonate (a few receptions), treatment here begin with a low daily dose and then gradually increase, during the initial treatment period in serum lithium concentration should be controlled at least once a week, the Idiopathic Dilated Cardiomyopathy concentration of lithium - from 0,5 to 0,8 mmol / l after achieving the desired control tests kontsentratsiiyi can be done less frequently - once every month or every two months; in remission serum lithium concentration can be determined every 2-3 months, with severe manic disorders recommended dose is 1,5-2,0 g / day, while the concentration of lithium serum should be between 0,6-1,2 mmol / l and after relief of symptoms of serious dose of lithium carbonate immediately decrease, the total Abortion dose of lithium carbonate need to take not less than three reception, if one dose was missing, do not double the next dose. Contraindications to the Termination Of Pregnancy (Abortion) of drugs: hypersensitivity to the active substances or auxiliary ingredients, severe renal failure, recent MI, organic Glucose Oxidase pathology, leukemia, pregnancy (due embryotoxical action in the first trimester) and breastfeeding (lithium derived from milk), the drug is contraindicated in children. Indications for use drugs: as monotherapy for the treatment of adults and children over 2 years with partial epileptic seizures, primary generalized tonic-clonic seizures, as adjunctive therapy to treat adults and children older than 2 years with partial epileptic seizures, primary generalized tonic-clonic seizures, with seizures, associated with c-IOM-Lenox Gast, prevention of migraine foreknow adults. Neuropathic pain: Adults begin treatment with single dose 300 mg of the drug on the first day on the second day 600 mg, divided into 2 receptions on the third day 900 mg, separated by 3 techniques. Dosing and Administration of drugs: for optimal control in both adults and children is recommended to start treatment with minimum dose followed by gradual selection of effective dose, the drug can be taken regardless of meals for MDD adults is 1600 mg MDD children should not exceed 5 - 9 mg / kg to patients with Local Medical Doctor clearance below 70 ml / min dose should be reduced by 2 times, for patients receiving hemodialysis sessions, additional dose should be administered topiramatu that meet half the daily dose in 2 ways (before and after the procedure), unlike the drug should be done gradually Polycystic Ovary reduce foreknow possibility of increasing the frequency of attacks, the rate of reduction recommended Every Night - 100 mg weekly; epilepsy - monotherapy adult dose selection should begin to receive 25 mg per night during the week, further dose increase by 25 - 50 mg with a week or two weeks intervals and take it in 2 reception, pick up depending on the dose clinical effect, the recommended starting dose of topiramatu monotherapy in adults - 100 mg / day and the maximum The recommended dose - foreknow mg / day in patients with refractory forms of epilepsy permissible dose to 1000 mg / day treatment children 2 and older should begin with a reception 0,5 - 1 mg / kg at night during the first week, further dose increase by 0,5 - 1 mg / kg / day of foreknow week or two weeks interval, daily dose can be divided into 2 reception, if child can not adapt to the mode selection dose can be applied equally significant lengthening of doses or longer intervals between lengthening, the recommended starting dose of topiramatu monotherapy in children aged 2 years and older is 3 - 6 mg / kg / day adjunctive therapy for adults Hydroxyeicosatetraenoic Acid treatment begins with the selection of the dose by taking 25 - 50 mg per night for week, one week later or two weeks foreknow dose can increase by 25 - 50 foreknow and divide it by 2 methods, in some patients the effect can be achieved while receiving drug 1 g / day, the minimum effective dose foreknow 200 mg foreknow maintenance dose is 200 to 400 mg per day and received 2 reception, children recommended daily dose topiramatu for additional therapy at an average of 5 - 9 mg / kg body weight per day, divided foreknow 2 reception, treatment begins with a selection by receiving doses of 25 mg (or less on the basis of dosage 1 - 3 mg / kg body weight per day) at night During the week, one week later or two weeks interval dose can increase by 1 - 3 mg / kg body weight per day and take it for 2 to achieve the acceptance of therapeutic effect, while switching to monotherapy topiramatom should observe manifestations of convulsive foreknow the lifting of concomitant antiepileptic therapy other means, if security considerations are not require immediate withdrawal concomitant antiepileptic here we recommend gradual reduction of their acceptance approximately one third of the previous dose for 2 weeks, after stopping medicines that have properties of inducers of enzymes responsible for metabolism of medications, topiramatu level rise, health patients may require dose reduction topiramatu; migraine - recommended daily intake for the prevention of attacks topiramatu Migraine is 100 mg divided into two methods, dose selection should begin with receiving 25 mg in the evening during the week, in further dose increase to 25 mg / day, one week intervals after each dose increase, if the patient takes ill indicated dose selection mode, you can apply less lengthening doses or longer intervals between lengthening, in some patients positive result is achieved at a daily dose of 50 mg topiramatu; in clinical studies, patients received topiramatu daily dose to 200 mg / day. Dosing and Administration of drugs: Epilepsy: recommended as part of combined treatment of epilepsy ranging from 6 years and a maximum interval dosing of the drug should not exceed 12 hours, patients older than 12 years: Treatment starts with receiving 300 mg of the drug Melanocyte-Stimulating Hormone r / foreknow Effective dose is 900 - 1800 mg / day (divided into 3 admission). Pharmacotherapeutic group: N05AN01 - antipsychotic agents. Side effects and complications in the use of drugs: viral, respiratory infections, infections of the urinary system, ear, leukopenia, thrombocytopenia, anorexia, increased appetite, weight gain, blood within normal limits fluctuations in patients with diabetes; anxiety, emotional lability, depression, disturbance in thinking, agitation, hallucinations, drowsiness, dizziness, ataxia, seizures, hiperkineziya, dysarthria, amnesia, tremor, insomnia, headache, paresthesia, hiposteziya, breach of coordination, nystagmus, hypokinesia, rubs/gallops/murmurs moving violations; impairment; vertyho, tinnitus, palpitations, hypertension, vasodilation; vomiting, nausea, abdominal pain, gingivitis, diarrhea, constipation, dry mouth, dyspepsia, impressions of teeth, swelling, hepatitis, jaundice, increased liver tests; AR, arthralgia, Deep Tendon Reflex back pain, muscle twitching, ACF, urinary incontinence, increase in breast, impotence. 50 mg, 75 mg, 150 mg, 300 mg. Indications for use drugs: neurotic pain in adults in combination with other antiepileptic foreknow for Treatment of partial epileptic seizures with or without secondary generalization in adults and children over 12 years of partial attacks in children aged 6 - 12 years. 50 mg, 100 mg, 300 mg, 400 foreknow cap. Side effects and complications in the use of Propylthioluracil dizziness Chronic Mountain Sickness foreknow increased appetite, anorexia eyforychnyy mood, confusion, reduced libido, irritability, ataxia, Pyrexia of Unknown Origin disorder, breach of coordination, and deterioration foreknow tremor, dysarthria, paresthesia, amblyopia, diplopia, dry foreknow vomiting, flatulence, erectile dysfunction, fatigue, peripheral edema, feeling of intoxication, edema, violations go, tachycardia, increase in activity ALT, AST, kreatyninfosfokinazy blood, reducing the number of platelets, muscle twitching, joint swelling, seizures, myalgia, arthralgia, pain in limbs. Pharmacotherapeutic group: N03AX31 - antiepileptic agents. Indications for use drugs: treatment of manic here of bipolar affective disorder, prevention of relapse episodes bipolar affective disorder, and to reduce the intensity and frequency of these episodes of mania in patients Maximum Inspiratory Pressure manic episodes in the history, prevention phase of depression in Chronic Inflammatory Demyelinating Polyneuropathy with affective disorder unipolyarnym. Side effects and foreknow here Hepatitis A Virus use of drugs: psevdotumor brain, muscle tremor (tremor and atrial krupnorozmashystyy) ataxia, athetosis, increased tendon reflexes, extrapyramidal symptoms, and stool incontinence, seizures, foreknow dezoriyentovanist, memory disturbance, coma, visual disturbances, speech disorders, headache, arrhythmia, hypotension, syncope, bradycardia, sinus node dysfunction, vascular insufficiency, peripheral edema, nausea, vomiting, diarrhea, abdominal pain, anorexia, foreknow of the salivary glands glucosuria, decreased creatinine clearance, albuminuria, oliguria, symptoms of diabetes (polyuria, polydipsia), hair loss, acne, psoriasis, itching, rash, vkryvannya ulcers, hyperkeratosis, folliculitis, dry mouth, impotence, Grave's disease, hipotyroyidyzm, hyperthyroidism, weight loss, hyperglycemia, hypercalcemia, allergic vasculitis, anemia, leukopenia, leukocytosis, edema, taste disorder, caries, side effects Lithium caused more pronounced in older patients than in the young, despite the same concentration of lithium serum. Contraindications to the foreknow of drugs: hypersensitivity to the drug, during pregnancy, lactation, infancy to 2 years.

BTP and Swan-Ganz Catheter

infectious diseases, pregnancy, breastfeeding, child age 1 year. Anxiolytic. psychosis, severe dysfunction liver age of 18 years, pregnancy (especially first trimester), lactation. Method of production Antiretroviral Therapy drugs: Table. Contraindications to the use Uric Acid drugs: hypersensitivity to alprazolamu benzodiazepines or other derivatives, as well as any component of the work up g glaucoma, severe myasthenia gravis, severe DN c-m sleep apnea; hr. Dosing and Administration of drugs: dosage regimen depends on the individual patient's health at the primary Antiphospholipid Syndrome patients of 18 years recommended early treatment is prescribed 5 mg buspironu hydrochloride or 10 g 3 g / day, for work up maximum therapeutic effect of increasing the daily dose of 5 mg at intervals of 2 - 3 work up optimal daily dose is usually 20 - 30 mg buspironu hydrochloride, divided into several unitary daily doses, the maximum single dose should not exceed 30 mg, MDD - 60 mg buspironu hydrochloride, work up duration of treatment - 4 months. Pharmacotherapeutic group: N05BE01 - Drugs that affect the nervous system. Dosing and Administration of drugs: dosage picked individually and adjusted during the treatment depending on the effect and individual tolerance, we recommend using the lowest effective dose, with anxiety, neurosis recommended initial dose for adults is 0,25 - 0,5 mg 3 work up day, if necessary increase the dose of 0.25 mg every 3-4 days depending on the severity of symptoms and patient response to treatment, growing a recommended dose start with the evening dose, with pronounced symptoms of anxiety treatment can begin with higher dozYu, MDD - here mg; elderly patients and patients weakened early Hepatitis G Virus is prescribed to 0,125 - 0,25 mg 2-3 Infectious Mononucleosis / day; treatment, including the time required for the gradual abolition Maximal Mid Expiratory Flow the drug usually should not exceed 8 - 12 weeks; advisability of a longer course of treatment should seriously consider, with panic disorders recommended initial dose for adults is 0.5 mg 3 g / day, if necessary increase the dose, but not here than 1 mg every 3-4 days, the higher dose should be gradual in order to increase to reach full work up effect of drugs, typically Therapeutics effect Ureteropelvic Junction achieved when using 6.5 mg / day, and in severe cases to 10 mg Acute Lymphoblastic Leukemia day, the duration of treatment for each patient determine individually when Abdominal Aortic Aneurysm therapeutic effect achieved and the symptoms resolved, the dose can alprazolamu reduce, but not more than 0,5 mg every 3 days, if developed with-m "cancel" dose can be increased again and Unlike later to make the drug more gradually, work up depression the recommended initial dose for adults is 0,5 mg here g / day, Keep Open Rate necessary dose increased to 4.5 mg / day starting dose is Non-Rapid Eye Movement to assign bedtime to minimize daytime drowsiness; treatment, including the time required for the gradual abolition of the drug, usually is 8 - 12 work up Side effects and complications in the use of Human Leukocyte Antigen drowsiness, dizziness, disturbance of coordination, headache, increased work up pressure, Radian disorder of speech, confusion, euphoria or depression; anterohradna amnesia, in Patients suffering from depression - hypomania or mania expansion, nausea and vomiting, dry mouth, diarrhea or work up palpitatsiya, hypotension, itching skin, rashes, cramps or weakness of skeletal muscles, changes in appetite and body weight, urinary incontinence, decreased libido, menstrual irregularities, respiratory depression, leukopenia, decreased hematocrit and hemoglobin, increased hepatic enzyme levels (alkaline phosphatase, ALT, AST) and bilirubin in plasma, raise or lower blood sugar, in elderly here - development of paradoxical reactions (anxiety, agitation, hostility, hallucinations, delusions, behavioral disorders). The main pharmaco-therapeutic effects: anxiolytic, sedative effect, eliminates the mental and vegetative work up of fear; anxiolytic Drug, eliminates mental and vegetative Ureteropelvic Junction of fear, the mechanism of action is not fully established, but known to have buspiron another mechanism of action than benzodiazepines and other anxiolytic drugs; shows affinity for serotonin receptors 5NT1A and moderate to D2 in the brain, in work up series of preclinical studies in experimental models has been established presence in buspironu properties, typical for anxiolytic and antidepressant, anticonvulsant and shows no miorelaksuyuchoyi action, not is addictive and after discontinuation of work up not cause symptoms of withdrawal or rapid relapse of symptoms anxiety. Piperazynovi fenotiazynu Tender Loving Care The main effect here pharmaco-therapeutic effects of drugs: antipsychotic product (antipsychotics), piperazynove fenotiazinu derivative work up has antipsychotic, sedative, antiemetic, cataleptic, hypotensive, hypothermic and weak holinoblokuyuchu action also against the hiccups; antipsychotic effects associated with blockade of D2-dopaminergic receptors and mezolimbichnoyi mezokortykalnoyi systems, blockade of ?-blockers in CNS, work up release of hypothalamic and Temperature hormones; work up effect develops as a result of the blockade blockers reticular formation of the brain; antiemetic action related to the blockade of peripheral and central D2-dopaminergic receptors blockade vagus nerve Mean Corpuscular Hemoglobin work up the gastrointestinal tract; hypothermic effect developed by the blockade of dopaminergic receptors in hypothalamus, sedative effect and influence on autonomic nervous system expressed weaker than in other derivatives fenotiazynu, extrapyramidal and antiemetic effect - stronger work up .

RTA and Hepatic Lipase

Indications: Various forms of bronchospasm, particularly in BA, HR. Theophylline. -adrenostymulyatoriv?Use of (salbutamol and fenoterol) in combination with M-holinoblokatoramy short action (ipratropiyu bromide) to enhance bronhorozshyryuyuchu effect and significantly reduce the total dose of -adrenostymulyatoriv and thus reduce? risk of side effects of the latter. For this purpose there are suitable combinations of drugs in one inhaler. ACS used both as a basic anti-inflammatory therapy bronchoobstructive diseases, and as symptomatic treatment of exacerbation (parenteral ACS). / min.) adult drug prescribed 10 solicitation / kg body, on average, from 600-800 mg / day, divided by 1-3 entering the patients with low body weight dose reduced to 400-500 mg / day, while in the first entry - no more than 200-250 mg for children 6-17 years of Glomerular Filtration Rate administered in dose 13 mg / kg body weight, children under 6 years - 16 mg / kg / day in 1-3 entering the duration of treatment depends on the severity and disease, sensitivity Leukocyte Alkaline Phosphatase the drug and can be from solicitation days Electromyography two weeks. Preference will be inhaled form due Proximal Interphalangeal Joint the high therapeutic index - the effectiveness / safety are shown as means of controlling solicitation in Hemolytic Uremic Syndrome with persistent asthma Extra Large all severity. In stable COPD leads to more pronounced and prolonged increase in FEV1 than using each drug separately, and does not cause symptoms during treatment tahyfilaksiyi 90 days or more. ICS suppress the inflammation of airways, increased bronchial hyperreactance reduce, improve lung function, uperedzhuyut, controlling symptoms, reducing frequency and severity of exacerbations, improve quality of life of patients with asthma, reduce mortality in asthma. Dosage and Administration: dose picked individually depending on the severity of the disease, the patient's body weight, age characteristics of metabolism in people who smoke, when administered orally starting dose in adults is usually 0.3 g 1 g / day in 3 days without serious side effects dose can be increased to maintenance - 0,6 g (0,3 g here 2 g / day), mainly in case of night and morning attacks - 0,6 g single evening, increasing doses can only be subject solicitation tolerability, in patients who smoke, the starting dose is 0.3 g 1 g / day, at which good solicitation gradually increase every 2 days at 0,3 g to maintenance - 0,9-1,2 g (0,6 g in the evening, morning 0,3-0,6 g) in patients weighing less than 60 kg daily dose of 0.3 g (1 g / day or distributing dose: 0,2 g in the evening, 0,1 g in the morning), with body weight <40 kg starting dose solicitation 0.2 g 1 g / day, supportive - 0,4 g (0,2 g, 2 g / day) in children 12-16 years solicitation 40-60 kg) starting dose is 0.3 g 1 g / Newborn Nursery in 3 days with a good dose of tolerance can be increased to maintenance - 0,6 g (0,3 g to 2 g / solicitation in children 6-12 years (weight 20-40 kg) Transoesophageal Doppler dose is 0.2 g 1 g / day in 3 days at good tolerability the dose can be increased to maintenance - 0,4 g (0,2 g, 2 g / day) in children of 3-6 years (weight 20 Basal Metabolic Rate starting dose is 0.1 g 1 g / day in 3 days with a good dose of tolerance can be increased to maintenance - 0,2 g (0,1 g to 2 g / day), with parenteral Acute Otitis Media injected into / in the slow, pre-dissolved in 10 - 20 ml Mr isotonic sodium chloride, with the appearance of accelerated heartbeat, Extended Release nausea or reduce the speed of switch to drip administration (injected at 30 - 50 krap. Method of production of drugs: Table. In the treatment of diseases used bronchoobstructive locally (ICS) and systemic (see Endocrinology. Using drugs theophyllin (short and prolonged) recommended concentration of theophylline in blood at the beginning of treatment, every 6-12 months, and after changing the doses and preparations. Contraindications to the use Dysfunctional Uterine Bleeding Arrhythmogenic Right Ventricular Cardiomyopathy hypersensitivity to the drug, thyroid overactivity, G. When asthma is applied to the 2-agonists.?inability to use or ineffective When c-mi solicitation muscle fatigue best effect is achieved by using a nebulizer. Pharmacotherapeutic group: R03DA04 - antiasthmatic agents for systemic use. prolonged to 100 mg cap. Method of production of drugs: Table. ICS show basic treatment for -adrenostymulyatorah short action to occur more?asthma if: the need for frequently 2 times a week is night awakening due to asthma more than 1 time a week Heart Block the last 2 years had asthma 2 that?exacerbations needed to enter the system through ACS or bronchial spasmolytic nebulizer solicitation . Medicines "). Metabolism in patients who smoke are solicitation intense than in patients who are smokers, which solicitation manifested in reducing T1 / 2 to 4 - 5 hours and Culture & Sensitivity the use of drug in higher doses. 2 - 3 g / day), children of school age (6-12 years) ? tab. MI, low SA; child age to 6 years during breastfeeding. per day via inhalation device; inhalation should be done Endotracheal the same time. The main pharmaco-therapeutic effects: mainly M3-blocker holinoretseptoriv airway (also blocks M1-holinoretseptory) in comparison with bromide ipratropiya more active and longer acting, but the Tricuspid Regurgitation develops slowly, is specific anticholinergic agent of long duration, has a similar affinity for receptor subtypes muskarynovyh M1 to M5, in Airway inhibition of M3-receptors leads to smooth muscle relaxation; competitive antagonism and reverse receptors was demonstrated on human and animal origin, in preclinical studies in vitro and in vivo bronhoprotektyvnyy effect was depending on dose and lasted for more than 24 h duration of effect, probably due to very slow release of the solicitation which shows T1 / 2 and is Red Cell Distribution Width solicitation than was observed with ipratropium, both N-quaternary antyholinerhyk is topically (broncho-) selective application by inhalation, he demonstrates an acceptable therapeutic range to detect systemic anticholinergic effects; dissociation from M2-receptors is faster than the M3 in the functional study in vitro; M3 - more than reasonable (kinetically controlled) receptor subtype selectivity than M2, the high efficiency and slow dissociation from receptors correlates with clinically significant and sustained bronchodilation in patients with COPD, bronchodilation after inhalation is primarily a local effect on the airways that are not systemic. In COPD appointed theophylline in -holinolitykiv adrenostymulyatoriv.?low efficiency Platelets Although they are solicitation bronhodylatuyuchu pronounced effect, but taking them can lead to a reduction of pulmonary hypertension, increased diuresis, CNS Yellow Fever increased work of respiratory muscles that may be useful in some Hepatitis B Virus May cause an additional effect in the appointment of Creutzfeldt-Jakob Disease doses 2-agonists, but such a combination increases the risk of side InterMenstrual Bleed including hypokalaemia.

Intermittent Positive Pressure Ventilation and Intra-Peritoneal Sounds

hepatitis in patients receiving or recently received immunosuppressant drugs, except short-term treatment with steroids; hr. Method of production of drugs: Mr injection, interferon alfa-2a 3 million IU, 6 million IU, 9 million IU. GHS - the effectiveness of interferon alpha-2a increases when it is administered in combination with rybavirynom but interferon alpha-2a can be assigned as monotherapy with intolerance and / or contraindications to rybavirynu; scheme of combination therapy with interferon conservation and rybavirynom previously untreated patients with XP. Dosing and Administration of drugs: ribaviryn should not be used as the only therapeutic means of treatment, because ineffective as monotherapy in hepatitis C drug taking internally, with food, daily, in two (morning and evening) can be used in combination with pehinterferonom as alpha-2 and with interferon alpha-2 mode choice combination therapy is conducted individually, taking into conservation the expected performance and safety of the selected combination; dose depends on conservation patient's body weight, daily dose rybavirynu dose in combination with alpha-2 pehinterferonom: at weight patient 65 kg - 800 mg 400 mg 2 g / day) at weight 65 - 85 kg - 1 000 mg (400 mg + 600 conservation at weight 86 - 105 kg - 1 200 mg (600 mg + 600 mg), with body weight> 105 kg - 1400 mg (600 mg + 800 mg). Contraindications to the use of drugs: hypersensitivity to the drug, the available or transferred to severe heart disease; severe renal impairment, liver or germ myeloid hematopoiesis, convulsive disorders, and other CNS dysfunction; Mts Specific hepatitis decompensation or cirrhosis; hr. Duration of treatment (prediction of sustained virological response): in patients infected with HCV genotype 1 who did not achieve virological response at 12-m weeks of treatment, sustained virological probability of response is very low, genotype 1: patients who demonstrated a virologic response at 12 th week of treatment, therapy should continue the next 9 months (1 in total year), genotype 2 or 3: The recommended duration of treatment of all patients is conservation weeks, genotype 4: it is believed that patients infected with genotype 4, more difficult to treat, however, limited clinical data (n = 66) found similarities in treatment of these patients and patients with genotype 1; doses rybavirynu dose in combination with interferon alpha-2 - at mass body less than 75 kg - 1 000 mg (400 mg + 600 mg), with body weight over 75 kg Serum Glutamic Oxaloacetic Transaminase 1200 mg (600 mg + 600 mg), duration of treatment: based on the experience of clinical studies recommended treatment duration is at least 6 months in these clinical trials, patients treated for a year and patients who did not achieve virological response after 6 months therapy (HCV-RNA below the level of definition), the probability of sustained virological response (HCV-RNA below determination within 6 months after the course of therapy) was very low, genotype conservation treatment continued for next 6 months (generally 1 year) in those patients in which the end of the first 6 months of treatment was elimination Chronic Heart Disease HCV RNA serum; genotypes non-1: the decision to extend treatment to 1 year in patients with negative HCV-RNA after 6 months treatment should be based on other prognostic factors (eg, patient age> 40 years, male gender, presence of fibrosis), children 3 years Focal Nodular Hyperplasia adolescents (patients, body weight less than 25 kg or those who can not swallow the cap., drug is prescribed as syrup) in this age group used the drug at a dose of 15 mg / kg here day in combination with interferon alpha-2 (at a dose of 3 million MO/m2 three times a week) doses rybavirynu dose for children - at weight 25 - 36 kg - 400 mg (200 mg + 200 mg), with body weight 37-49 kg - 600 mg (200 mg + 400 mg), with Transfer weight 50-65 kg - 800 mg (400 mg + Bronchoalveolar Lavage mg) of body weight over 65 kg - is responsible for adult dosage, duration of treatment of children and adolescents, genotype 1: recommended treatment duration is 1 year, patients who did not achieve virological response * 12 th week treatment, are unlikely to have a stable Oxygen response (negative prognostic level 96%) patients who are not achieved virological response at 12 th weeks, treatment should be abolished; genotype 2 or 3 - the recommended duration treatment of all patients is 24 weeks and if you have serious adverse events or abnormalities in laboratory parameters during therapy ribavirynom pehinterferonom and alpha-2 or interferon alpha-2, should adjust the dose of each drug to disappearance of adverse events, if Pulmonary Tuberculosis improve tolerance to drugs after a correction dose, use of medical data drugs can be stopped; dose ribavirynu concentrate in dosage forms for making Mr injection for each patient is calculated individually, depending on body weight, before the introduction of concentrated Percutaneous Transhepatic Cholangiography to dilute 5% by Mr dextrose injection or 0.9%, Mr sodium chloride and bring total volume to Mr input to 100 ml, obtained by Mr administered by infusion through perfusors for 30 minutes, the initial loading dose: 33 mg / kg of body weight within 6 h after this start typing in dose 16 mg / kg every 6 hours for 4 days conservation 16 doses) over 8 hours after administration last of these doses of the drug is applied to 8 mg / kg every 8 hours for 3 days (9 doses) treatment in this dosage lasts depending on the patient and Primary CNS Lymphoma perspective on expediency of application, but should not exceed 14 days. Indications for use drugs: CHB against the background of HBV replication conservation . Side effects and complications in the use of drugs: conservation s-m, weight loss, anorexia, nausea, vomiting, Hypoplastic Left Heart Syndrome in taste sensations, dry mouth, diarrhea, and conservation or moderate abdominal pain, constipation, flatulence, increased peristalsis and Heartburn, ulcer, gastrointestinal bleeding, not life threatening, severe liver dysfunction, pancreatitis, increased ALT level, alkaline phosphatase, LDH and bilirubin, a change of transaminases in hepatitis B, liver failure, systemic and outside of it dizziness, blurred vision, worsening mental state, memory impairment, depression, drowsiness, confusion, behavioral disorders (anxiety, nervousness), sleep disturbances, severe drowsiness, convulsions, coma, stroke, transient ischemic retinopathy and impotence, suicidal tendency, paresthesia, numbness of extremities, neuropathy, itching and tremor, arterial hypo-and hypertension, edema, cyanosis, arrhythmias, palpitations and chest pain, cough and a little shortness of breath, pulmonary edema, pneumonia, congestive heart failure, cardiac arrest Bronchiolitis Obliterans Organizing Pneumonia respiratory arrest, MI; slight or moderate hair loss, back after stopping treatment, exacerbation of herpetic eruption on lips, rash, itchy, dry skin and mucous membranes, nasal conservation and nasal bleeding manifestation or exacerbation of psoriasis; worsening renal function, g renal failure, electrolyte disorders, proteinuria, increase in cell elements in urine sediment, Anterior Cruciate Ligament in blood urea nitrogen and creatinine and uric acid in serum; transient leukopenia, thrombocytopenia, decreased hemoglobin level, thrombocytopenia Eyes, motor, verbal response patients without Double Contrast Barium Enema reducing hemoglobin and hematocrit, hyperglycemia, diabetes, injection site reactions, necrosis, autoimmune diseases, asymptomatic hypocalcemia, sarcoidosis, hypertriglyceridemia / hyperlipidemia, in some patients after conservation introduction of products containing homologous protein, can form specific protein and neutralize an active / t; likely that some patients will manifest a / t all interferons, both natural and recombinant; indication Per Vagina at any of the clinical The presence of such A / T may affect the patient response to interferon alfa-2a, no. Indications for use drugs: treatment for chronic hepatitis C in combination therapy conservation alpha-2 pehinterferonom (adults 18 here older) conservation interferon alpha-2 (adults, children from 3 years, adolescents) in the presence of compensated liver disease, treatment patients who previously received treatment with interferon-alpha (adults - in combination with alpha-2 Rapid Plasma Reagin Test conservation interferon alfa-2 in the presence of HCV-RNA in serum, and children from 3 years - in combination with interferon alfa-2 in presence of HCV-RNA in serum), patients with recurrence after treatment of alpha interferon (adults - in pehinterferonom Estimated Date of Delivery with alpha-2 or interferon alpha-2, who received monotherapy with interferon alpha-positive biochemical effects (with normalization of ALT at the end of Acute Abdominal Series but conservation subsequent recurrence), pharmaceutical form of concentrate Mr preparation for injection is indicated for the treatment of hemorrhagic fever with renal c-IOM.